BenjaminEvansPetersonMDMPH

Interventional Cardiology

Interventional cardiologist Structural heart program Medical Director Heart and Vascular Research Institute

Dr. Peterson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
711 Medical Village Dr
Edgewood, KY 41017
Phone+1 859-287-3045

Fax+1 859-578-3800

Benjamin Peterson, MD, is a cardiologist specializing in interventional cardiology based in Edgewood, KY. He completed his fellowship in cardiovascular disease at Brigham and Women's Hospital from 2016 to 2019 and previously did his residency in internal medicine at Duke University Hospital. He graduated from the University of Rochester School of Medicine and Dentistry in 2013. Dr. Peterson currently works as an interventional cardiologist at St Elizabeth HealthCare, having previously held similar positions at Kent Hospital and Newton-Wellesley Hospital. His research includes several published works on cardiovascular interventions, with some receiving citations from other publications.

PubMed

Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry.
Benjamin E Peterson, Deepak L Bhatt, Christie M Ballantyne, James A de Lemos, Robert S Rosenson
International Journal of Cardiology. 2025-02-15
3 citations
Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease.
Benjamin E Peterson, Deepak L Bhatt, Christie M Ballantyne, James A de Lemos, Robert S Rosenson
JAMA Network Open. 2023-03-01
24 citations
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton
Journal of the American Heart Association. 2022-03-15

Addition of Icosapent Ethyl Cuts CV Risk in Patients with Prior PCIMarch 24th, 2022
Amarin’s Vascepa Shows Lower Risk of Fatal CV Events in REDUCE-IT Prior PCI Post Hoc SubanalysisMarch 10th, 2022
REDUCE-IT: Significant Reduction in Coronary Revascularizations with Icosapent EthylMay 15th, 2020